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Although some progress has been made in our understanding of
pancreatic carcinogenesis, the cause of this highly malignant
disease still remains unknown. It generally grows without
presenting symptoms until late in its history and thus poses many
problems for the diagnosing physician. A mere 5–22% of tumours
are detected early enough to allow radical resection (Trede et al,
1990; Eskelinen et al, 1991; Warshaw and Fernandez-del Castillo,
1992; Janes et al, 1996), the only hope for cure. Although in recent
selective studies, 5-year survival rates of up to 17–27% have been
reported for curative resection of pancreatic cancer (Trede et al,
1990, 1998; Warshaw and Fernandez-del Castillo, 1992; Yeo et al,
1995), even those patients surviving pancreatic cancer for 5 years
often die of local or metastatic late recurrence (Trede et al, 1998).
It appears that the results of surgical treatment alone have reached
a plateau in pancreatic cancer.
Since our understanding of the mechanisms of pancreatic
carcinogenesis has broadened, new treatment strategies might be
devised to blunt the biological aggressiveness of these tumours. A
sound foundation for studies into tumour growth and progression
as well as new treatment modalities in pancreatic cancer would be
the development of a reproducible animal model. The two main
rodent pancreatic cancer models, the nitrosoamine-induced
hamster model and the azaserine-induced rat model have been
extensively documented (Longnecker and Curphey, 1975; Pour et
al, 1977, 1981, 1991; Longnecker et al, 1981, 1992; Pour, 1984;
Egami et al, 1991; Pettengill et al, 1993; Mäkinen et al, 1998). In 
a preliminary study, we have reported that a tumour cell line
(DSL-6A/C1), originally derived from an azaserine-induced
primary tumour (Pettengill et al, 1993), produced a solid and
uniformly growing tumour when it was transplanted subcuta-
neously (s.c.) (Mäkinen et al, 1998). However, there are no studies
available on the growth pattern and microvasculature of rat intra-
pancreatic tumours induced with cultured carcinoma cells. In this
study we describe the tumour take, growth and microvasculature,
and subsequently evaluate the feasibility of this animal model for
use in pancreatic cancer studies.
MATERIALS AND METHODS
Animals
Male Lewis rats (n = 120) were obtained from Charles River
Laboratories (Sulzfeld, Germany). For transplantation, 5-week-old
rats (± 1 week) with initial weights of about 100 g were used.
Studies and growth characteristics were based on five different
transplantation series. The animals were kept under standard labo-
ratory conditions, fed a chow diet, observed daily and autopsied if
showing lethargy, ulcers, swelling or weight loss. All animal
procedures were approved by the Animal Care and Use
Committee of the University of Kuopio.
Tumour cell line and transplantation
Tumour cell line DSL-6A/C1 (ATCC CRL-2132) was obtained
from an acinar cell carcinoma (DSL-6) of rat pancreas (Pettengill
et al, 1993). Cell culture and characteristics of s.c. transplanted
tumours have been reported previously (Pettengill et al, 1993;
Mäkinen et al, 1998). In brief, for pancreatic tumour induction, 
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DOI: 10.1054/ bjoc.1999.1017, available online at http://www.idealibrary.com on 20 ml containing 2 ´ 106 carcinoma cells were injected through the
pancreatic capsule into the pancreatic tissue at the splenic lobe
(Figure 1) using Hamilton syringe (Hamilton Bonaduz AG,
Switzerland) with 26-gauge needle and a stereotactic apparatus
(Kopf, Germany). To prevent carcinoma cell spread after the injec-
tion, Tisseel fibrin glue (Immuno AG, Austria) was applied over
the pancreas around the needle and after a 1-min delay the needle
was slowly withdrawn.
Tissue samples
At autopsy, 2–28 weeks after tumour induction, all tumours were
removed, and their dimensions measured. The samples were then
processed for light microscopy studies. The tumour volume was
calculated in cubic centimeters. Abdomen and thoracic cavity
were examined systematically throughout and all abnormal tissues
were sampled and processed for microscopic examination.
Microangiography
The method used has been described earlier (Kormano, 1967).
Microangiography studies were carried out in untreated (n = 2) as
well as in tumour-bearing animals (n = 7). Microangiography was
performed by infusing 10% barium sulphate solution
(MicropaqueR, Nicholas, France) into the abdominal aorta under
80–120 mmHg pressure until the pancreatic microvasculature was
filled with contrast material. The whole pancreas was then
removed and fixed in 4% buffered formaldehyde solution and
embedded in paraffin. Five hundred-micrometer sections were cut
for microangiography and adjacent 5 mm sections were cut and
stained with haematoxylin and eosin (H&E) for histological
studies. The microangiography slices were X-rayed with high
resolution plates (KodakR), using a Siemens X-ray tube equipped
with a tungsten anode and a beryllium window. The focus-to-film
distance was 53 cm, and exposure values were 18 min, 40 kV and
20 mA. H&E samples were used for orientation and to confirm the
borders of the tissue structures.
Statistical analysis
In statistical analysis, the SPSS/PC+ program package (SPSS Inc,
Chicago, II, USA) was used.
RESULTS
Recovery after successful tumour cell inoculation was uneventful.
The tumour take was 64% (77/120). At laparotomy the earliest
palpable nodules were found 2 weeks after inoculation, but in
some animals tumours became palpable only after 15 weeks. If
there had been any technical problems in inoculation (i.e. carci-
noma cell spreading) tumour tissue was found also around the
peritoneum, mainly in the wound scars already after 2 weeks. The
increase in tumour volume is shown in Figure 2. After 20 weeks
the tumours usually had attained 1 cm3 volume and in half of the
experimental animals the tumours were still local. The others
showed invasive growth around the peritoneum, gut mesentery,
spleen, liver hilus, liver, kidneys and retroperitoneum. Ulcerative
growth through the abdominal wall was found in the largest
tumours. No distant metastases were found outside the abdomen.
The consistency of tumours were hard. The cut surface was
homogenous and pale, however, cystic changes were found in the
largest (> 2.0 cm3) tumours as well as the necrotic areas.
Desmoplasia was a common finding. Tumour infiltrating lympho-
cytes and plasma cells as well as the granulocytes and giant cells
of foreign type were found, although the inflammatory reaction
was usually mild. All tumours were ductal adenocarcinomas
showing usually moderate differentiation grade (Figure 3). No
signs of perineural invasion were found.
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Figure 1 Intrapancreatic tumour induction by injecting 2 million cultured
DSL-6A/C1 carcinoma cells in 20 ml volume into the splenic lobe of Lewis rat
pancreas. Injected carcinoma cells were seen in pancreas under the
pancreatic capsule (arrow). Fibrin glue was applied over the injection area to
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Figure 2 The growth curve for Lewis rat intrapancreatic tumours. Each
value is the mean ± s.e.m. of pancreatic tumour volumes measured from
5–10 animalsThe microvasculature, as well as arterioles and arteries, of
pancreases were well filled with contrast medium. No ruptured
vessels were found. Microangiography of normal rat pancreata
showed that the vessels sprout like branches into a dense capillary
network around pancreatic acini. The capillary structure was
regular in shape and size. Pancreatic tumours exhibited deficits in
their microcirculation. Tumour vessels were irregularly organized,
slender, thin and straight ‘finger-like’ structures. There were avas-
cular areas in the centre of the tumours. The peritumoural area
showed dense neovascularization and vessel invasion (Figure 4).
DISCUSSION
We have previously found that a tumour cell line (DSL-6A/C1)
derived from azaserine-induced rat pancreatic tumour (Pettengill
et al, 1993) produced a solid and uniformly growing tumour when
it was transplanted s.c. into the Lewis rat (Mäkinen et al, 1998).
However, our long-term strategy was to establish an intrapancre-
atic tumour model with a solid tumour nodule in the pancreas for
pancreatic cancer studies, to be subjected to detailed examination
in gene therapy studies.
In this experimental study we have demonstrated a reasonable
tumour take and reproducible growth pattern after intrapancreatic
tumour cell inoculation. In our series, 77 of 120 animals had
pancreatic tumours when autopsied. A number of animals did not
have palpable tumours until 15 weeks after cell inoculation. Since
a few animals were autopsied before 15 weeks, those animals
which did not have tumours at that time, would after all become
tumour-bearing if they would have lived longer. Consequently, we
believe that the actual tumour take was somewhat higher than 64%.
We conducted five different transplantation series and tumour
take varied between these series although the cell culture,
harvesting, animal age and inoculation techniques were similar.
One explanation may be that tumourigenicity of the cell line
varies. It is also possible that immunocompetent animals can
destroy tumour cells to varying degrees. Although the inflamma-
tory reaction within the tumours and in the peritumoural area was
usually mild, some variation did exist. Interestingly, some animals
that did not have tumours had inflammatory reaction with giant
cells of foreign type, and some had also few atypical ductal cells as
well as desmoplasia. In addition, some samples showed intense
inflammation, as seen in the number of plasma cells and lympho-
cytes. This may be a reflection of immune rejection and tumour
cell killing through graft-versus-host response. Consequently, if
we had used immunodeficient animals the results might have been
more favourable in regard to induction of tumours. However, the
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Figure 3 Histologic appearance of pancreatic tumour taken 12 weeks after
DSL-6A/Cl carcinoma cell inoculation exhibiting a moderately differentiated
adenocarcinoma (right) growing infiltratively into normal pancreatic tissue
(left). Scale bar = 100 mm
Figure 4 Microangiography of the border between a pancreatic tumour
(lower part) and normal pancreatic tissue (upper part) taken 15 weeks after
carcinoma cell inoculation. Vessel network filled with contrast media invades
into tumour tissue (A). Adjacent haematoxylin and eosin-stained section
showing the border between induced carcinoma and normal pancreatic
A B
Figure 4 Microangiography of the border between a pancreatic tumour (right) and normal pancreatic tissue (left) taken 15 weeks after carcinoma cell
inoculation. Vessel network filled with contrast media invades into tumour tissue (A). Adjacent haematoxylin and eosin-stained section showing the border
between induced carcinoma and normal pancreatic tissue (B). Scale bar 5 100 mmRat pancreatic tumour 903
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experiments then would have been much more complicated and
the linkage of this model to human disease would have been
diminished.
Intrapancreatic tumour induction with small fragments of rapidly
growing azaserine-induced primary tumour was originally
presented by Longnecker (1981). In this model pancreatic tumours
grew rapidly, reaching 2–3 cm dimension in 3 weeks. This model
has been adapted in intrapancreatically as well as in s.c.-induced
tumours (Aprahamian et al, 1993; Karsently et al, 1993; Evrard et
al, 1994). Although tumours induced with cultured cells grew more
slowly, experimental tumours induced with a homogenous cell
population may offer advantages with respect to similar biological
behaviour. Our results concerning the phenotype and growth char-
acteristics seem to confirm this hypothesis. Furthermore, a rodent
tumour model with slowly progressing malignant tumour may
provide better predictability when compared with models of very
rapidly dividing and spreading rodent carcinoma cells.
In rats, azaserine treatment produces pancreatic tumours that
arise from altered acinar cells (Longnecker, 1987). However, when
these tumour cells were cultured and regrafted s.c. in Lewis rats,
they produced duct-like carcinoma (Pettengill et al, 1993). As
presented previously (Mäkinen et al, 1998) and in this study, intra-
pancreatic tumours induced with cultured cells also exhibited a
ductal phenotype. The reason for this phenotypic plasticity has
been discussed previously (Hall and Lemoine, 1993; Pettengill et
al, 1993). Although DSL-6A/C1 cells produce ductal pancreatic
carcinoma, there are some similarities with this tumour model and
human acinar cell carcinoma of the pancreas as reported previ-
ously (Klimstra et al, 1992). The metastatic disease in their mate-
rial was largely limited to the upper part of the abdomen. They
also found recurrent tumour in the abdominal or chest wall and
considered this as a consequence of carcinoma implantation in the
surgical resection tracts. In our experimental model, the tumour
spread was also limited to intra-abdominal organs and tumour
dissemination to the abdominal wall around the scars was a
common finding.
Experimental tumours showed deficits in their microvasculature
with the shape of vessels being straight but their structure irreg-
ular. This is due, at least in part, to the necrosis and desmoplasia
found in tumours. Previously, the microangiography technique has
been used to analyse microcirculatory changes in experimental
pancreatitis and hypovolemic shock (Nuutinen et al, 1986, 1988).
These studies showed that poor filling of capillaries during haem-
orrhagic or necrotizing pancreatitis may be due to disruption of
capillaries, vascular thrombosis or shunting of blood away from
the capillary circulation. In addition, pancreatic ducts in the
necrotic areas of severe acutic pancreatitis, as well as the ductal
walls in chronic pancreatitis, showed a decrease in their vascu-
larity (Pitkäranta et al, 1991). The dense vessel network in the
peritumoural area was a particularly interesting finding of the
present study. This may be a consequence of angiogenic switch,
through changes in the balance between angiogenic activators and
inhibitors (Hanahan and Folkman, 1996). Consequently, the
tumour cells may either induce the production or even synthesize
themselves mediators that stimulate angiogenesis, an essential
factor for expansion of the tumour mass. This could be elucidated
by analysing known angiogenic inducers, such as vascular
endothelial growth factor and fibroblast growth factors before and
during tumourigenesis. However, this is only one of many prob-
lems remaining to be answered.
We observed that a tumour cell line (DSL-6A/C1), derived from
an azaserine-induced rat pancreatic tumour (DSL-6), produced a
solid and uniformly growing tumour when transplanted intrapan-
creatically into the Lewis rat, providing a feasible model for
pancreatic cancer studies.
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